title: Treatment of sepsis in the surgical intensive care unit.
abstract: Since the Surviving Sepsis Campaign Guidelines (SSG) were published in 2004, critical care physicians can readily access the evidence and current recommendations regarding management of patients with severe sepsis and septic shock. However, several issues including a potential conflict of interest in developing the guidelines were disclosed. There have also been dramatic changes in the management of sepsis, supported by high levels of evidence. SSG 2008 was developed to update the evidence using a new grading system. We reviewed select topics, routinely addressed by intensivists in the surgical intensive care unit, that have changed between SSG 2004 and SSG 2008: namely, glucose control, and administration of steroids, recombinant human activated protein C (rhAPC) and total parenteral nutrition.
authors.affiliation: Wellspan Health, York, PA, USA.
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Carney
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Matsushima
authors.forename: Heidi L
authors.initials: HL
authors.lastname: Frankel
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001786:Blood Glucose; D006801:Humans; D007362:Intensive Care Units / Q000592:standards*; D010288:Parenteral Nutrition / Q000379:methods; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D000890:Anti-Infective Agents; D001786:Blood Glucose; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated